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Protective effects of breastfeeding on respiratory symptoms in infants with 17q21 
asthma risk variants 
To the Editor: 
Genetic polymorphisms at the 17q21 locus have been associated with the subsequent onset of 
childhood asthma and appear to strengthen the association between childhood asthma and 
early episodes of wheezing.(1, 2) A recent study of Loss et al.(2) showed that 17q21 alleles 
modified the effect of exposure to older siblings and animal shed on episodes of wheeze in 
infancy. Since environmental factors seem to play a role with respect to the effect 
modification by the 17q21 polymorphism, our aim was to assess whether the association 
between asthma-associated 17q21 variants, and lower respiratory symptoms during the 1
st
 
year of life, may be modified by breastfeeding. In addition, we investigated whether the 
described interactions with other environmental exposures, such as older siblings(2) and 
tobacco exposure,(3, 4) were reproducible.  
We tested our hypothesis within the prospective Basel-Bern Infant Lung Development 
(BILD) birth cohort of healthy unselected infants (n=368) living in urban environments.(5) 
Parental written informed consent was obtained and the study was approved by the ethics 
committees of Basel and Bern. Respiratory symptoms, such as occurrence of cough, wheeze 
or difficulty breathing during the night and day - and their severity -were assessed by weekly 
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telephone interviews using a standardized symptom score (each on a scale of 0-4, with 0 
indicating no symptoms and ≥3 severe symptoms).(5) As a primary outcome, the respiratory 
symptoms score was calculated as a sum total of daytime and nighttime symptoms scores (on 
a scale of 0-8).(5) The secondary outcome was episodes of wheeze in the 1
st
 year of life that 
were defined as a whistling sound in the chest audible to the parents, or doctor-diagnosed 
wheeze.  Wheeze episodes have been recorded since 2004 on a weekly basis (based on a “yes 
or no” question); therefore, we restricted our sample to those infants with complete 
information on wheeze (n=252). 
Genome-wide genotyping was performed using Illumina HumanOmniExpress Bead Chips 
(Illumina Inc., San Diego, USA). Five major tagging SNPs at the locus 17q21: rs7216389, 
rs4795405, rs8079416, rs8065126 and rs3902025 were included in the analysis. These 
variants were selected as representative of the five highest asthma-associated tagging bins 
based on unpublished 17q21 fine mapping data (1,446 children, 763 asthmatics, from the 
German MAGIC and ISAAC II studies), presented at the 11
th
 Meeting of the European 
Human Genetics Societies. For the purposes of our study, either the major tagging SNP from 
the respective bin was analyzed (rs3902025), or a proxy in high linkage disequilibrium. 
Generalized additive mixed model with quasi Poisson and Binomial distribution for count 
and binary outcomes was used to investigate weekly measured respiratory symptom scores 
and any breastfeeding ( “yes or no” for each week under observation). We applied 
autoregressive AR(1) modeling to account for inter-child variation. Each SNP was coded as 
0/1/2 for the number of risk alleles and analyzed separately under the additive model. The 
interaction was tested by adding to the adjusted model the multiplicative interaction term 
between breastfeeding and SNP.  
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Next we attempted a replication of top SNPs within the Protection against Allergy Study in 
Rural Environments (PASTURE) birth cohort study (n=799) that was conducted in rural 
areas. Information on respiratory symptoms (defined as the presence of wheeze or cough) and 
any breastfeeding was collected from weekly and 4-weekly diaries. We used a stringent 
Bonferroni P-value correction threshold of 0.01 (0.05/5) and 0.025 (0.05/2) for discovery and 
replication analysis, respectively. Further information on demographic (eTable 1) and 
genotype characteristics, methods and meta-analyses of both cohorts are provided in the 
Supplement. 
The 17q21 SNPs were not associated with respiratory symptoms score during the 1
st
 year of 
life. When we stratified infants by breastfeeding status, we found that, during those weeks 
when infants were breastfed, the carriers of asthma risk alleles of the most strongly associated 
SNPs (rs7216389-T and rs4795405-C, Table 1) were more responsive to the protective effect 
of breastfeeding on respiratory symptoms. In contrast, during those weeks when infants were 
not breastfed, the same genotype showed a trend towards an increased risk for respiratory 
symptoms, resulting in a significant interaction effect for both SNPs (P for interaction 0.0006 
and 0.0041, respectively, Table 1). Though the direction of the association in the entire 
wheeze subset of infants, and across strata by breastfeeding, was the same as in the main 
analysis, no significant interaction was observed between the 17q21 locus and breastfeeding 
in relation to wheeze that may be explained by limited power and conservative correction for 
multiple comparisons. 
In the PASTURE cohort, the protective effect of breastfeeding on wheeze was present only in 
carriers of asthma risk alleles of rs8076131 (the closest proxy of rs4795405, r
2
=0.92; r
2
-value 
is based on a study by Toncheva et al (6)) (Figure 1). Similar effects were observed in 
carriers of risk alleles of rs4795405 in relation to wheeze in the BILD cohort. However, we 
found no evidence for an interaction. The meta-analysis of interaction effects in the BILD 
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and PASTURE data yield a borderline significant effect for rs4795405 (P-value=0.028, 
eFigure 1 in the Supplement). Factors that may weaken the breastfeeding interaction in the 
PASTURE cohort were population specific genetic and environmental factors, such as high 
farm exposure and an interaction of breastfeeding status with farming exposure in relation to 
respiratory symptoms (data not shown). We hypothesize that the influence of the 17q21 locus 
on respiratory symptoms may be modified by multiple environmental factors, and their 
relative small size impact may depend on the environmental context. 
In accordance with Loss et al.(2), we were able to replicate the interaction between the 17q21 
locus and the presence of older siblings. Consistent with other studies(2, 3), we did not find 
interaction with maternal smoking during pregnancy (eTable 2 in the Supplement). 
There are several interpretations we can consider on the interaction between 17q21 SNPs and 
breastfeeding in relation to respiratory symptoms. First, breast milk is rich in immune 
components inhibiting virus replication, regulating mucosal immunity(7), and shifting the gut 
microbiota towards species which strengthen the immune response.(8) Secondly, the 17q21 
locus may increase susceptibility to viral infection.(1) Thirdly, DNA methylation in CpG 
cites of rs7216389 and rs4795405 was associated with mRNA expression of Orosomucoid 
like 3 (ORMDL3) gene.(9) This would make carriers of the asthma risk genotype potentially 
more responsive to the protective effect of breastfeeding. Finally, epigenetic phenomena are 
known to be related to 17q21.(10)  
In conclusion, our findings demonstrated evidence suggestive of interaction between 17q21 
variants and breastfeeding in relation to respiratory symptoms in the 1
st
 year of life. Infants 
with the asthma risk allele might particularly profit from the protective effect of breastfeeding 
on early-life respiratory infection, which is an important target for secondary asthma 
prevention. Since multiple exposures seem to affect 17q21 in a complex manner, observed 
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gene-environment interactions may be specific for a given environment (e.g. rural versus 
urban context). 
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Table 1. Association
a
 of 17q21 genotype (addtive effect for risk allele) with 
respiratory symptoms and wheeze by breastfeeding 
 
 
 
 
 
 
 
SNP 
 
 
 
 
 
Risk 
allele 
Total Stratum by exposure  
 
 
P-value 
Interaction
b 
 
 
Weeks with 
breastfeeding 
Weeks without 
breastfeeding 
RR (95% CI)/ 
OR (95% CI) 
RR (95% CI)/ 
OR (95% CI) 
RR (95% CI)/ 
OR (95% CI) 
Discovery: BILD (n=368 and 252 for respiratory symptoms and wheeze, respectively) 
Respiratory 
symproms
d
 
 No. of weeks= 
19,252 
No. of weeks= 12,511 No. of weeks= 
6,741 
 
rs7216389 T 0.98 (0.90-1.08)
 
0.82 (0.72-0.93) 1.09 (0.96-1.24) 0.0006 
rs4795405 C 1.03 (0.94-1.12) 0.85 (0.74-0.97) 1.10 (0.97-1.24) 0.0041 
rs8079416 C 1.07 (0.98-1.16) 0.97 (0.85-1.11) 1.07 (0.94-1.21) 0.217 
rs8065126 C 1.10 (1.01-1.21) 1.01 (0.88-1.15) 1.12 (0.98-1.26) 0.125 
rs3902025 T 1.10 (1.00-1.10) 1.01 (0.88-1.16) 1.12 (0.98-1.27) 0.204 
Wheeze
e
  No. of weeks= 
13,101 
No. of weeks= 
8,564 
No. of weeks= 
4,537 
 
rs7216389 T 0.91 (0.67-1.22) 0.65 (0.39-1.09) 1.12 (0.76-1.67) 0.052 
rs4795405 C 0.90 (0.67-1.22) 0.59 (0.34-1.02) 1.17 (0.79-1.73)
 
0.020 
rs8079416 C 1.15 (0.85-1.57) 1.05 (0.62-1.76) 1.25 (0.84-1.88) 0.718 
rs8065126 C 1.08 (0.77-1.51) 0.69 (0.40-1.17) 1.46 (0.93-2.28) 0.037 
rs3902025 T 1.16 (0.84-1.61) 0.89 (0.50-1.57) 1.37 (090-2.08) 0.253 
Replication: PASTURE (n=799) 
Respiratory 
symproms
e
 
 No. of weeks= 
31,691 
No. of weeks= 
14,734 
No. of weeks= 
16,957 
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rs7216389 T 1.10 (1.02-1.19) 1.11 (0.98-1.27) 1.11 (1.00-1.22) 0.689 
rs8076131 A 1.06 (0.98-1.14) 0.99 (0.88-1.33) 1.11 (1.01-1.22) 0.370 
Wheeze
e
      
rs7216389 T 1.10 (0.95-1.26) 1.03 (0.81-1.31) 1.15 (0.97-1.36) 0.799 
rs8076131 A 1.12 (0.97-1.29) 0.95 (0.74-1.20) 1.24 (1.04-1.46) 0.174 
Abbreviations: BILD, Basel-Bern Infant Lung Development birth cohort; PASTURE, Protection against Allergy 
Study in Rural Environments birth cohort; OR, odds ratio; RR, risk ratio; CI, confidence interval. 
a
 adjusted for sex, week of age, presence of older siblings, birth weight, gestational age, mode of delivery, child care, 
maternal education, maternal/parental atopy, maternal smoking in pregnancy, week of, and study centers. In the 
replication analysis the association was additionally adjusted for farm exposure. 
b
 Interaction was tested by adding the product between breastfeeding and corresponding SNP in the adjusted model.  
c 
Per-allele RR and 95% CI derived from generalized additive mixed model with quasi-Poisson distribution. 
d 
Per-allele OR and 95% CI derived from generalized additive mixed model with Binomial distribution. 
Significant associations after Bonferroni correction are in boldface. 
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Figure 1: Associations of breastfeeding with respiratory symptoms and wheeze in the 
BILD discovery cohort and in PASTURE replication cohort according to rs7216389 
and rs4795405 (the proxy is rs8076131): (A) respiratory symptoms and rs7216389; (B) 
wheeze and rs7216389; (C) respiratory symptoms and rs4795405 (the proxy is 
rs8076131); (D) wheeze and rs4795405 (the proxy is rs8076131). 
Associations (*Bonferroni-significance) were adjusted for sex, week of age, presence of 
older siblings, birth weight, gestational age, mode of delivery, child care, maternal education, 
maternal/parental atopy, maternal smoking in pregnancy, week of, and study centers. In the 
replication cohort the association was additionally adjusted for farm exposure. Results were 
expressed as a risk ratio (RR) for the association between respiratory symptoms score in the 
BILD cohort and as an odds ratio (OR) for other associations. All estimates are given with 
95% confidence interval (95% CI).  
  
